BMS-663513

DRUG3 trials

Sponsors

Bristol-Myers Squibb

Conditions

Advanced Solid MalignanciesNon Small Cell Lung CancerTumors

Phase 1

Study of BMS-663513 in Patients With Advanced Cancer

TerminatedNCT00309023

Bristol-Myers SquibbTumors

Start: 2005-12-31End: 2009-09-30Updated: 2015-10-12

A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies

TerminatedNCT00351325

Bristol-Myers SquibbAdvanced Solid Malignancies

Start: 2007-09-30End: 2009-03-31Target: 45Updated: 2009-09-04

A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)

TerminatedNCT00461110

Bristol-Myers SquibbNon Small Cell Lung Cancer

Start: 2008-01-31End: 2009-04-30Target: 35Updated: 2009-09-04

Related Papers

Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer2024-03-0123 citations

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma

American Journal of Hematology2020-02-1395 citations